Again, Ibrutinib was only able to impair IL-6 or IL-10 expression in ABC DLBCL cells that express CD79 mutants, but not in CARMA1 L244P expressing OCI-Ly3 cells. Here, IL10 is linked to diffuse large B-cell lymphoma.